Skip to main content

Table 5 Analysis of survival outcomes in different subgroups of the IMRT group versus the IMRT/chemo-therapy group

From: Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma

FactorOSPDFSPLRRFSPDMFSP
Age
 ≤ 45 years86.7% vs. 96.0%0.28280.0% vs. 92.0%0.23893.3% vs. 96.0%0.69686.7% vs. 96.0%0.299
 > 45 years93.6% vs. 86.5%0.25789.4% vs. 86.5%0.62097.9% vs. 94.6%0.41593.6% vs. 94.6%0.369
Sex
 Male90.9% vs. 90.9%.0.98084.1% vs. 88.6%0.58195.5% vs. 93.2%0.64390.9% vs. 95.5%0.708
 Female94.4% vs. 88.9%0.55394.4% vs. 88.9%0.553100% vs .100%1.00094.4% vs. 94.4%0.504
T category
 T1100% vs. 94.4%0.378100% vs. 94.4%0.378100% vs. 94.4%0.378100% vs. 100%1.000
 T292.7% vs. 94.1%0.82587.8% vs. 91.2%0.63997.6% vs. 94.1%0.45290.2% vs. 94.1%0.571
 T371.4% vs 70.0%0.90751.1% vs. 70.0%0.791100% vs. 100%1.00071.4% vs. 90.0%0.362
N category
 N090.5% vs. 84.2%0.53985.7% vs. 84.2%0.81795.2% vs. 100%0.34295.2% vs. 94.7%0.215
 N192.7% vs. 93.0%0.96487.8% vs. 90.7%0.67897.6% vs. 93.0%0.33190.2% vs. 95.3%0.389
TNM stage
 II94.5% vs. 94.2%0.93590.9% vs.92.3%0.80298.2% vs.94.2%0.28392.7% vs. 96.2%0.462
 III (T3N0M0)71.4% vs. 70.0%0.90757.1% vs.70.0%0.80185.7% vs.100%0.23285.7% vs. 90.0%0.648
  1. OS Overall survival, DFS Disease-free survival, LRRFS Locoregional relapse–free survival, DMFS Distant metastasis–free survival